End-of-day quote
Nigerian S.E.
18:00:00 2024-07-14 EDT
5-day change
1st Jan Change
1.7
NGN
0.00%
-1.73%
-12.37%
NEIMETH INTERNATIONAL PHARMACEUTICALS : QUARTER 4 - FINANCIAL STATEMENT FOR 2022
January 30, 2023 at 10:14 am
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
FINANCIAL STATEMENTS 31 DECEMBER 2022
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2022
Contents
Page
Statement of financial position
1
Statement of profit or loss and other comprehensive income
2
Statement of changes in equity
3
Statement of cash flows
4
Notes to the financial statements
5 - 44
Other national disclosures:
Statement of value added
45
Financial summary
46
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 DECEMBER 2022
3 Months
15 Months
12 Months
ended
ended
ended
% G+(-)
31-Dec-22
31-Dec-22
30-Sep-21
Note
N'000
N'000
N'000
Turnover
8
946,300
3,649,153
3,046,661
20%
Cost of sales
9
(674,273)
(2,275,001)
(1,601,458)
42%
Gross profit / (Loss)
272,027
1,374,152
1,445,203
-5%
Other income
10
9,774
35,938
202,023
-82%
Marketing and distribution expenses
11
(179,430)
(755,772)
(579,694)
30%
Administrative expenses
12
(172,560)
(749,293)
(513,938)
46%
Exchange Gain / (Loss)
13
(90,663)
6,224
(93)
-6792%
Operating (Loss) / Profit
(160,852)
(88,749)
553,501
-116%
Finance costs
14
(19,455)
(201,221)
(188,216)
7%
(Loss) / Profit before taxation
(180,307)
(289,972)
365,285
-179%
Income tax expense
28
-
-
(94,708)
-100%
(Loss)/Profit for the year from continued operation
-
180,307
-
289,972
270,577
-207%
Other comprehensive income
Gain on available for sale assets
-
-
Total other comprehensive income
-
-
-
Total comprehensive (Loss)/Profit
(180,307)
(289,972)
270,577
-207%
Basic (loss)/earnings per share
32
-9%
(15)
14.25
The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 DECEMBER 2022
Ordinary
Share
Retained
shares
premium
earnings
Total equity
N'000
N'000
N'000
N'000
At 1 October 2020
949,579
112,606
212,476
1,274,661
Changes in equity the year
Profit for the year
-
-
270,576
270,576
Other comprehensive income
-
-
-
-
Total comprehensive profit for the year
-
-
270,576
270,576
Dividend declared and paid
-
-
(123,445)
(123,445)
Transaction costs for equity issue
-
(7,726)
-
(7,726)
At 30 SEPTEMBER 2021
949,579
104,880
359,608
1,414,067
At 1 October 2021
949,579
104,880
359,608
1,414,067
Changes in equity for the Period
Loss for the year
-
-
(289,972)
(289,972)
Other comprehensive income
-
-
-
-
Total comprehensive Loss for the quarte
-
-
(289,972)
(289,972)
Dividend declared and paid
-
-
(132,941)
(132,941)
Transaction costs for equity issue
-
(96,060)
-
(96,060)
At 31 December 2022
949,579
8,820
(63,305)
895,094
This is an excerpt of the original content. To continue reading it, access the original document here .
Disclaimer
Neimeth International Pharmaceuticals plc published this content on 30 January 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 30 January 2023 15:13:09 UTC .
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the First Quarter Ended March 31, 2024
05-30
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023
01-30
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
01-30
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-30
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-07-31
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-28
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Fifteen Months Ended December 31, 2022
23-01-30
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
23-01-30
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Fourth Quarter Ended September 30, 2022
22-10-28
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended September 30, 2022
22-10-28
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022
22-07-29
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022
22-04-29
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the First Quarter Ended December 31, 2021
22-02-02
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended September 30, 2021
21-12-29
CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Third Quarter Ended June 30, 2021
21-07-30
CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Second Quarter Ended March 31, 2021
21-04-30
CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the First Quarter Ended December 31, 2020
21-01-29
CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended September 30, 2020
20-11-13
CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Third Quarter Ended June 30, 2020
20-07-29
CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Second Quarter Ended March 31, 2020
20-05-11
CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended December 31, 2019
20-01-30
CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Full Year Ended September 30, 2019
19-12-23
CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Third Quarter Ended June 30, 2019
19-07-30
CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Second Quarter Ended March 31, 2019
19-04-30
CI
Neimeth International Pharmaceuticals Plc. Reports Earnings Results for the First Quarter Ended December 31, 2018
19-01-29
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Neimeth International Pharmaceuticals Plc is a Nigeria-based company, which is engaged in the manufacturing and marketing of pharmaceuticals and animal health products. The Company operates through two segments: Pharmaceuticals product group and Animal health product group. Pharmaceuticals product group is engaged in the marketing and sales of the Company's branded products and the products under the consumer product group. Animal health product group is engaged in the marketing and sales of poultry and animal range of anthelmintics, as well as production medicaments. Its products include Ethical Products, Veterinary Products, and Healthcare Products. Its Ethical Products include Ciklavit, Flucosyd, Amlovar, Norduet, and Normoretic, among others. Veterinary Products include Neimeth Piperazine, Neimycin Chick powder, and Neiva Stress. Its Healthcare Products include Antimal, Homtamin G, Urah, and Pancemol, among others. The Company operates in two geographic regions: Nigeria and Ghana.
More about the company
Average target price
1.75
NGN
Spread / Average Target
+2.94%
Consensus
1st Jan change
Capi.
-12.37% 4.64M +62.92% 856B +39.26% 631B -3.64% 359B +18.30% 325B +9.19% 297B +5.89% 234B +16.77% 226B +16.30% 177B +2.29% 165B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1